Microfluidic Flows Enter Medical Mainstream
Microfluidic Readouts Could Flag Problems and Open the Door for New Treatment and Potential Early Intervention
Downstream Processing Builds Pure Intensity
Bioprocessing Favors Go with the Flow over Stop and Go
Tumor Biomarkers Culled from Errant Transcripts
Potential for Blood Platelet–Derived Biomarkers to ID and Locate Tumors
Sequencing Within Reach
An Orthogonal Approach to Genome Sequencing
The Sounds of Science podcast is brought to you by GEN. Listen as members of the editorial team—Editor-in-Chief John Sterling, Technical Editor Jeff Buguliskis, and Senior News Editor Alex Philippidis—showcase innovative research, new initiatives, and important policy by interviewing thought-leaders, eminent life-science researchers, and company leaders. These short, but informative podcasts will keep you up-to-date with the latest and most important life science advances.
Raphael Farzan-Kashani, a director with the New York City Economic Development Corp., discusses the city’s plans for a $100 million Applied Life Sciences Hub—part of a 10-year, $500 million plan to attract 16,000 new life-sci jobs and catapult the Big Apple into a top-tier biopharma cluster.
Having the right data and knowing how to use it will be the key to success in the healthcare market in the future.
Canadian team identifies protein that when hindered decreases invasion rate of cancer cells.
Researchers discovered that corneal cells isolated from human donors and grown on a dome-shaped surface behaved differently than those on flat one. There are a number of advantages to using such curved substrates.
Millipore is using its expertise in biomanufacturing to take advantage of the growing interest in continuous or next generation bioprocessing. The company is investing in specific technologies in terms of dedicated teams, focused R&D efforts, and product-development projects.
Researchers at MIT and Brigham and Women's Hospital create triggerable tough hydrogels. Hydrogels may last in stomach for lengthy periods of time.
Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.
A research team from Vanderbilt University, University of North Carolina, and Gilead Sciences has just released new findings in Science Translational Medicine that a new antiviral drug candidate inhibits a broad range of coronaviruses, including SARS and MERS.
Team believes a rational therapeutic design approach will allow scientists to transform how the disease is tackled. Quantum dot technology also should be applicable to other autoimmune diseases as well.
A synthetic, soft tissue retina developed by an Oxford University doctoral chemistry student could offer fresh hope for visually impaired people.
Sara Radcliffe, President and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner.
A new test not only rapidly and inexpensively detects Zika virus in mosquitoes and human bodily fluids, but can also distinguish between African and Asian strains.
New research may eventually lead to orally ingestible bacteria for monitoring gut health and disease—with the ultimate goal being the development of a home inflammation test.
Mary Woolley, President of Research!America, which advocates for medical and health research funding, talks about how her group and other advocates plan to fight back against President Donald Trump’s one-two punch to NIH funding. Researchers will be key to those efforts, she says.
McGill University researchers may have found a natural way to cut down on antibiotic use without sacrificing health.
A recent study suggest that children with sensitive genotypes who come from low-income homes will be less financially successful than their same sex sibling without those genotypes. But children with those same genotypes from a high-income home would actually fare better economically as young adults than their brother or sister.
Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”?
Scientists have long written off cannibalism as a strange phenomenon with little biological significance. However, the true nature of cannibalism—the role it plays in evolution as well as human history—is even more intriguing (and more normal) than the misconceptions we’ve come to accept as fact.
Nicole M. Nichols, Ph.D., group leader for DNA amplification development at New England Biolabs, discusses the third national Genes in Space competition. The winner will have his or her experiment carried out aboard the International Space Station.
Bill Warren, partner with the law firm Eversheds Sutherland and chair of its biotechnology and life sciences team, discusses the ruling by a three-judge panel of the Patent Trial and Appeal Board siding with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology.